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diversity of the health professionals and the basic scenario. The costliest scenarios 
were the one implementing HPV DNA testing which did not provide further partici-
pation despite a high cost and the one based on P4P incentives towards GP, although 
it allows high participation rates. ConClusions: Using a comprehensive BIM, we 
show that full coverage of OS might be the most cost-effective way to implement it, 
although practical and financial issues might favour other scenarios that may be 
more balanced regarding the distribution of costs between stakeholders or may be 
more easily implemented and accepted by health professionals.
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Medicine supply of patients with CML is provided by means of federal state reim-
bursement program (FSRP) of high-cost nosologies and by regional budgets. Now, 
the reimbursement list of high-cost drugs includes only first generation tyros-
ine kinase inhibitor (TKI) – imatinib. However, there is a problem with access of 
patients with CML to second generation TKI because regional budgets are limited. 
Therefore, it’s important to provide pharmacoeconomic assessment of including 
second generation TKI into FSRP.objeCtives: To provide budget impact analysis 
(BIA) of including second generation TKI (nilotinib) into reimbursement list of high-
cost drugs of FSRP for second line treatment of patients with CML. Methods: BIA, 
as a part of this healtheconomic research was developed on the basis of decision 
tree and Markov model.The perspective of the study was FSRP of high-cost drugs, 
so direct costs for imatinib and nilotinib were considered.Real consumption of 
medicine was used.Tender prices of FSRP for imatinib and regional tender prices 
for nilotinib were used. Exchange rate 1Euro = 50Rub. Results: Annual cost per 
patient for imatinib for the first line CML patient in chronic phase was 6336Euro, 
while patients in accelerated phase and the second line treatment patients needed 
high dose imatinib treatment that costs 12672Euro.Annual cost per patient for 
nilotinib was 35040Euro.Total expenditures for first line treatment of CML with 
imatinib and the second line treatment with nilotinib for all CML patients were 
82,2 mln Euro.FSRP budget for CML in 2014 was 46 mln Euro, regional expenditures 
for the second line treatment with second generation TI of CML were above 44 
mln Euro.Therefore, including of nilotinib into FSRP leads to budget increase, but 
doesn’t exceed total current expenditures for CML of 90 mln Euro. ConClusions: 
Inclusion of nilotinib into FSRP does not exceed total current expenditures for CML 
and may improve patient access for effective treatment.
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objeCtives: The aim of the study was to conduct a health economic evaluation 
of using everolimus and axitinib in patients with metastatic renal cell carcinoma 
(mRCC). Methods: Cost-effectiveness analysis, budget impact analysis and sensi-
tivity analysis were performed. Progression-free survival and overall survival were 
included into the model as the effectiveness criteria. Decision tree model with Markov 
cycles was used. All direct costs were calculated from the healthcare system perspec-
tive. Stability of results to changes of external factors was evaluated by performing a 
probabilistic sensitivity analysis. Results: An analysis showed that the use of everoli-
mus was by 35% less expensive than the use of axitinib. At the same time a decrease in 
the probability of adverse event occurrence for everolimus, as well as an increase in the 
duration of overall survival by 27% were observed. The total cost per patient amounted 
to 1,686,463 RUB and 2,283,237 RUB when using everolimus and axitinib respectively. 
Compared to axitinib therapy, everolimus therapy is less expensive and at the same 
time, is more effective, i.e. it is dominant in relation to axitinib when considering such 
effectiveness criteria as overall survival and progression-free survival. The results of 
sensitivity analysis confirmed results of the baseline scenario regarding the economic 
feasibility of everolimus usage. The results of the budget impact analysis showed 
potential savings of budget finance in case of using everolimus, which provides an 
opportunity to treat additional patients with mRCC with no additional expenditures on 
the part of health care system. ConClusions: Everolimus showed a longer duration 
of overall survival in patients with mRCC after ineffectiveness of the first-line therapy. 
Moreover, everolimus therapy was less costly compared to axitinib therapy. Thus, the 
results of the study showed that the use of everolimus is a cost-effective strategy, as 
it is characterized by greater efficiency and lower costs.
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objeCtives: To compare cost of rituximab both Intravascular and subcutaneous for 
the treatment of NHL in patients within the social security and retiree segment And 
leaving in rural areas of ARGENTINA. Methods: Insurance given by two main sec-
tors were analysed. IOMA covers 157.741 beneficiaries while PAMI covers 215.118 . 1st 
line and 2nd line full treatments were calculated. As RTX cost is equivalent between 
formulations, we calculated the modules of the treatment including medical fee, 
materials etc. taking into account the IOMA value of USD 140.20 and PAMI one of 
USD 127.12 and the time of treatment in minutes we estimate the savings with the 
SC formulation. Results: IOMA Cost taking into account the consumption of time 
is around USD 1.190, 78 for the first line treatment and USD 899, 66 for the second 
as a second line treatment without increase of the total national CML budget 
in 2014.
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objeCtives: Castration resistant prostate cancer with bone metastases (mCRPC) is a 
common condition associated with high medical and indirect healthcare costs. Purpose 
of this analysis is to estimate the economic consequences of Radio-223 dichloride in the 
treatment of prostate cancer with definition of a Budget Impact Analysis (BIA) from the 
perspective of the National Health Service (NHS). Methods: Budget Impact analysis 
was carried to quantify the impact on the Italian National Health Service, in terms of 
costs of treatment given to the castration resistant prostate cancer (mCRPC), and as a 
result of the introduction of Radio-223 dichloride. In the assessment it was assumed 
that all the formulations present the same effect, ie that they present the same prob-
ability of efficacy in the treatment of metastatic castration resistant prostate cancer. The 
calculated values were applied to a population with mCRPC estimated the first year by 
about 4,009 people. Results: Considering the cost of the drug, the costs of administra-
tion, the cost of each adverse event, the total costs of each therapy, Radio-223 dichloride 
appears to have a lower cost than Abiraterone in both setting of patients in the first 
and second line treatment, lower than Enzalutamide in post-docetaxel population. The 
total costs were as follows: Radio-223 dichloride € 24,662.13; Abiraterone pre-Docetaxel € 
54,112.25, € 28,490.63 Abitaterone post-docetaxel, Cabazitaxel € 26,995.20, Enzalutamide 
€ 30,885.55 and finally Docetaxel € 4,574.69. Overall, looking at the scenario of the 1st 
and 2nd line following the introduction of Radio-223 dichloride it would generate sav-
ings of € 1,467,994 the first year, € 3,545,090 in the second year and finally € 7,660,642 in 
the third year. ConClusions: Treatment with Radio-223 dichloride turns out to have 
a favorable impact on the budget and appears to be the less expensive compared to 
other therapeutic strategies used in mCRPC in Italy.
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objeCtives: To determine the avoided cost derived from the opportune interven-
tion of the pharmacist before to the administration of schemes of chemotherapy 
avoiding medication errors (EM). Methods: A transverse analysis of EM’s record 
was realized (classification in accordance with Otero et al., 2000) in solid tumors, 
that evaluate the Clinical Pharmacy Service (CPS), in a period from November 2014 
to April 2015. The intention was to identify the cases of afebrile neutropenia (AN) 
before the application of the scheme of chemotherapy. The cost that had been gen-
erated by the handling of an uncomplicated febrile neutropenia were estimated, 
in accordance with the international recommendations of clinical practice, direct 
medical costs were considered: medicines (institutional catalog of prices), medical 
consultation, laboratory study and hospitalization from Official Federation Journal 
and groups related to the diagnosis IMSS 2015. Results: It was identified a whole 
of 365 (30 %) EM of 1195 pharmacotherapy follow-up, We found 22 patients who had 
AN, with an age average of 52 years, of which 54 % were women, this means 8% of 
total medication errors; 100 % of these errors of this patients group was a category 
“B” the error did not get the patient. The saving by the pharmaceutical interven-
tions was estimated in $80,228(USD), minus the cost of the prophylactic treatment 
after intervention ($13,624). The whole saving was $66,604, so that monthly average 
cost saved by CPS was of $11,101; there are 6 clinical pharmacists, that individu-
ally saved $1,850 monthly. The patients were rescheduled for their application of 
chemotherapy until cure the neutropenia, a prophylaxis was given for the subse-
quent cycles. ConClusions: The opportune intervention of the pharmacist in the 
identification and resolution of medication errors not only represents a clinical 
benefit in the safety of the patient, also is a monetary saving to the institution.
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objeCtives: Accordingly to the third Cancer plan, organized screening (OS) of cervical 
cancer among women aged 25-65 should be implemented in the forthcoming years in 
France. The most cost-effective way to implement OS in the French health care system 
in regard of this objective is yet to be determined. Methods: A budget impact model 
(BIM) was developed in collaboration with the French National Institute of Cancer 
(INCa) and an expert board involving clinical experts and stakeholder representa-
tives (social security, ministry of health, patients and professionals). Time horizon of 
the analysis is three years. Five plausible scenarios aimed towards the whole non-
participating population were assessed in the model. Those were derived from a 
basic scenario consisting of a mailed invitation followed by a mailed recall to which 
were added HPV DNA testing for women over 35, self-sampling kits sent to women 
over 35, pay for performance (P4P) incentives allocated to general practitioners (GP) 
whose eligible patients become participant, diversification of health professionals 
performing the sampling and full coverage of the screening by the statutory health 
insurance. Results: The “full coverage scenario” is the most cost-effective, followed 
by the scenario with self-sampling kits sent to women, the scenario with increased 
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chemotherapy after the index date to the earliest of mean time to HSCT, death, loss 
to follow-up, or last chemotherapy dose plus 30 days. The primary endpoint was 
the percent of time in the hospital during the salvage chemotherapy period. Key 
secondary endpoints were number of hospitalisations and length of hospital stay. 
Hospitalisations associated with HSCT were excluded. Results are presented as 
mean (SD) unless indicated. Results: Twenty-two patients were included, with 
a mean age of 44 (18) years. After the index date, 19 patients died and 8 patients 
received a HSCT. During the chemotherapy salvage period, patients spent a mean 
of 56% (95% CI: 46%-69%) of their time in the hospital. There were a mean of 2.2 
(1.5) inpatient hospitalisations, 3.2 (6.2) day stays, and 1.6 (3.0) outpatient visits per 
patient, and the mean length of inpatient hospitalisation was 20.0 (20.0) days. From 
the index date to death, there were a mean of 2.8 (1.4) inpatient hospitalisations, 
4.7 (7.3) day stays, and 4.6 (7.4) outpatient visits per patient and the mean length 
of inpatient hospitalisation was 19.0 (19.0) days. ConClusions: Adult patients 
receiving salvage chemotherapy for R/R ALL in Italy spend more than half their time 
in the hospital. Costs of hospitalisations will be presented.
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objeCtives: The goal of the study was to evaluate clinical and economic feasibil-
ity of nilotinib in comparison with the imatinib usage as the first-line therapy for 
chronic myeloid leukaemia (CML), and implementation of nilotinib compared with 
imatinib in high doses in the second-line treatment. Methods: Health-economic 
analysis and budget impact analysis of the use of tyrosine kinase inhibitors (TKI) for 
CML treatment were performed in Russian economic conditions. Economic models 
for the first and the second lines of CML treatment were built separately. Results: 
Analysis showed that use of nilotinib for patients with newly diagnosed CML as the 
first-line treatment and for patients with imatinib resistance or intolerability as 
the second-line treatment is accompanied by 36% increase of consolidated budget 
expenditures in 2015 compared to 2014 in theoretical consumption calculations. In 
terms of real consumption, use of nilotinib leads to 16% increase in consolidated 
budget expenditures in 2015, in comparison with 2014. Expected budget expenditure 
in 2015, taking into account actual consumption, is 5.8 billion RUB. The growth of 
state expenditure for CML treatment might be due to increase in the number of 
patients and the use of the second-generation TKI. In case of nilotinib use, with 
consideration of remission that allows therapy cancellation, the average cost of one 
CML patient treatment based on all lines of therapy in the registry per year will be 
decreased by 6% in 2018 compared to 2015, despite an increase in the number of 
patients in the registry. ConClusions: Nilotinib is characterized by greater effi-
ciency in the both lines of therapy. Using of the second-generation TKI, including 
nilotinib, can lead to stable remission with possible therapy cancellation after two 
or three years from the moment of deep molecular response. It may lead to the 
stabilization of cost per patient in the registry by 2018.
PCN80
hosPItalIsatIoNs amoNg adult PatIeNts wIth Ph-NegatIve 
B-PreCursor relaPsed or refraCtory (r/r) aCute lymPhoBlastIC 
leukaemIa (all) reCeIvINg ChemotheraPy IN germaNy:  
a retrosPeCtIve Chart revIew
Kreuzer K1, Stuhlmann R2, Lebioda A3, Reitan J4, Barber BL5, Barlev A6
1University of Cologne, Köln, Germany, 2Asklepios Hospital St Georg, Hamburg, Germany, 
3Amgen, Munich, Germany, 4RJM Group, Crown Point, IN, USA, 5Amgen Inc, Thousand Oaks, CA, 
USA, 6Amgen Ltd, Thousand Oaks, CA, USA
objeCtives: To determine time spent in the hospital by adult R/R ALL patients 
treated with current salvage chemotherapies in Germany. Methods: Adult 
patients hospitalised between 2003 and 2014 for Ph-negative R/R ALL were 
included. Eligible patients were relapsed with first remission lasting less than 
12 months, relapsed after first salvage therapy, relapsed any time after HSCT or 
refractory to primary induction or salvage therapy. Data were collected from the 
index date (first diagnosis of R/R ALL) until death or loss to follow-up. The salvage 
chemotherapy period started at the first chemotherapy after the index date to the 
earliest of mean time to HSCT, death, loss to follow-up, or last chemotherapy dose 
plus 30 days. The primary endpoint was the percent of time in the hospital dur-
ing the salvage chemotherapy period. Key secondary endpoints were number of 
hospitalisations and length of hospital stay. Hospitalisations associated with HSCT 
were excluded. Results are presented as mean (SD) unless indicated. Results: 
Twenty-one patients were included, with a mean age of 44 (16) years. After the 
index date, 17 patients died and 10 patients received a HSCT. During the salvage 
chemotherapy period, the mean percent of time spent in the hospital by patients 
was 58% (95% CI: 41%-75%). There was a mean of 1.5 (1.4) inpatient hospitalisa-
tions per patient with no day stays or outpatient visits, and the mean length of 
inpatient hospitalisation was 25 (20) days. From the index date to death, there 
were 3.5 (6.3) inpatient hospitalisations, no day stays, and 0.2 (0.6) outpatient 
visits per patient and the mean length of inpatient hospitalisation was 20 (27) 
days. ConClusions: Adult patients receiving salvage chemotherapy for R/R ALL 
in Germany spend more than half their time in the hospital. Costs of hospitalisa-
tions will be presented.
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line; meanwhile PAMI cost are around USD 1.079, 66 for the first line and USD 815, 70 
for the second one. Sc first line is USD 192, 98 per minute and USD 73, 61 per minute 
the second line for IOMA and PAMI SC USD 174, 97 per minute for the first one and 
USD 66, 74 per minute for the second one. Ratio between IV RTX cost and application 
is for IOMA 1 L 19.62 % and 14, 82 % 2 L; for PAMI the ratio for IV first line is 17, 78 % 
and for 2L 13, 44 %. SC represents IOMA 1 L 3, 18 % and 2L 1, 21 %, For PAMI is 2, 88 % 
1L and 1, 10 % 2L. El ahorro nominal por tratamiento es de USD 997, 80 para IOMA y 
de USD 904, 69 PAMI. ConClusions: nominal saving are around USD 997 for IOMA 
and 904, 69 for PAMI for treatment. IV takes 5,30 as average meanwhile SC just 27 
minutes that could improve patients quality of life.
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objeCtives: To assess hospitalization costs of patients with spinal tumors in 
France. Methods: All hospital stays with spinal tumors were extracted from the PMSI-
MCO 2012 database (French Medical Information System Program- Medicine, Surgery, 
Obstetric): ICD-10 codes C41.2 or C41.4 or C41.8 as principal/related or significantly 
associated diagnosis for primary tumors; association of ICD-10 codes C79.5 and M49.5 
as principal/related or significantly associated diagnosis or M49.5 alone as principal/
related diagnosis for secondary tumors. Patients were followed during one year from 
their first stay (e.g. March 2012/March 2013). An algorithm and a medical review excluded 
non spinal tumor related stays. Associated costs during this period were added up: a 
total annual cost (“burden”) as well as a mean annual cost per patient were estimated. 
Valuation was performed considering French official tariffs for 2012 and 2013 expressed 
in 2014 Euro. Results: 9,415 stays were extracted and considered as directly related to 
spinal tumors corresponding to 3,284 patients. Patients were 66±19 years old on average, 
55% were female. 94% of stays occurred in public hospitals. 56% of stays were ambulatory 
(length of stay, LOS = 0 day) and mean LOS associated with full hospitalizations was 
11±14 days. Spine fracture management, chemotherapy and radiotherapy accounted 
for 30%, 30% and 28% of stays, respectively. Overall, the economic annual burden of 
hospitalizations for spinal tumor reason was € 26 million; expensive drugs and implants 
funded in addition to DRGs (diagnosis related groups) accounted for 6% of this burden. 
The mean annual cost was € 7,817±8,858 per patient. ConClusions: Spinal tumors 
are mainly managed in public hospital. Hospital-related costs associated with spinal 
tumors are high. New spinal tumors treatment modalities could decrease these costs.
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objeCtives: This retrospective chart review aimed to quantify hospitalisations and 
costs among adult R/R ALL patients treated with current salvage chemotherapies 
in France. Methods: Eligible patients were aged ≥ 18 years and hospitalised from 
2003-2013 for Ph-negative R/R ALL. They were relapsed with first remission lasting 
< 12 months, relapsed after first salvage therapy, relapsed any time after HSCT, or 
refractory to initial or salvage therapy. Data were collected from the index date (first 
diagnosis of R/R ALL) until death or loss to follow-up. The salvage chemotherapy 
period was defined as the first chemotherapy hospitalisation after the index date 
to the earliest of mean time to HSCT, death, loss to follow-up, or last chemotherapy 
dose plus 30 days. The primary endpoint was the percent of time in the hospital 
during the salvage chemotherapy period. A key secondary endpoint was total costs 
from index date to death. Hospitalisations and costs associated with HSCT were 
excluded. Results: Thirty-three patients were included, with mean age of 49 years 
(range 19-75). The mean proportion of time patients spent in the hospital during 
the salvage chemotherapy period was 46% (95%CI: 34%-57%). The mean number of 
inpatient hospitalisations during the salvage chemotherapy period was 2.15 (1.5), and 
mean length stay was 17 (15) days. During the salvage chemotherapy period, the mean 
(SD) cost per hospitalisation was € 31,067 (€ 4,850) and the mean hospitalisation cost 
per patient was € 66,842 (€ 46,268). From the index date to death, there was a mean of 
3.67 inpatient hospitalizations, 4.27 day hospitalizations, and 0.7 outpatient visits. 
Corresponding mean (SD) costs per hospitalisation were € 28,832 (€ 8,867), € 674 (0), and 
€ 394 (0) respectively, for a total cost per patient of € 108,967. ConClusions: Adult 
patients receiving salvage chemotherapy for R/R ALL spend approximately half their 
time in the hospital, which is associated with large reimbursement costs in France.
PCN78
retrosPeCtIve Chart revIew of hosPItalIsatIoNs durINg 
ChemotheraPy for adult PatIeNts wIth Ph-NegatIve B-PreCursor 
relaPsed or refraCtory (r/r) aCute lymPhoBlastIC leukaemIa (all) IN 
Italy
Pagano L1, Oberti M2, Esposito B3, Reitan J4, Barlev A5, Barber BL6, Ferrara F7
1Università Cattolica del Sacro Cuore, Rome, Italy, 2Spedali Civili, Brescia, Italy, 3Amgen, Milan, 
Italy, 4RJM Group, Crown Point, IN, USA, 5Amgen Ltd, Thousand Oaks, CA, USA, 6Amgen Inc, 
Thousand Oaks, CA, USA, 7Cardarelli Hospital, Napoli, Italy
objeCtives: To quantify hospitalisations among adult R/R ALL patients treated 
with current salvage chemotherapies in Italy. Methods: Adult patients hospital-
ised from 2003–2014 for Ph-negative R/R ALL were included. Eligible patients were 
relapsed with first remission lasting less than 12 months, relapsed after first salvage 
therapy, relapsed any time after HSCT or refractory to primary induction or salvage 
therapy. Data were collected from the index date (first diagnosis of R/R ALL) until 
death or loss to follow-up. The salvage chemotherapy period encompassed the first 
